Market open· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
KDA Group (KDA.V) on Thursday said an evaluation of its digital platform Medherize in breast-cancer
KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the results of an independent evaluation of its digital platform Medherize, conducted by the Breast Disease Centre of CHU de Québec – Université Laval (Hôpital du Saint-Sacrement). Carried out among 243 patients with breast cancer on targeted oral therapies (CDK4/6 inhibitors) between September 2025 and March 2026, the evaluation demonstrate
KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the voting results of the annual general meeting of shareholders (the "Meeting") held on April 29, 2026, in Quebec.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.